|
To,
Mr. Sunil Jajoo
VP & Cluster Head, Dermatology
Sun Pharmaceutical Industries Ltd.
Dear {{$doctorName}},
Subject: Real World Evidence (RWE) Study of Bilastine
In response to your letter dated _________, I agree to participate in the study as outlined by you. I
understand that:
- You will provide me with a copy of the study plan, ___ CRF
- Bilastine will be prescribed as in my routine practice
- The patients’ identity will not be disclosed in the CRF
- I have to report serious adverse events (SAE), if any, immediately to your monitor or to you in the AE
reporting form
- You will provide the assistance of a monitor to verify the information in the CRF with that in the
patients’ case papers and reports
My personal details are given below for accuracy of your records.
|